Neurocrine Biosciences, Inc.
NBIX
Xếp hạng trong cổ phiếu
#1514
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Giá cổ phiếu
$141.77
Đồng bộ lần cuối: 2026-10-20
Vốn hóa thị trường
$14.41B
Thay đổi (1 ngày)
3.49%
Thay đổi (1 năm)
-0.62%
Quốc gia
US
Giao dịch Neurocrine Biosciences, Inc. (NBIX)
Danh mục
Healthcare
Doanh thu của Neurocrine Biosciences, Inc. (NBIX)
Doanh thu vào Jun 2026 TTM: $3.37B
Theo các báo cáo tài chính gần đây của Neurocrine Biosciences, Inc., doanh thu hiện tại của công ty (TTM) là $3.37B. Trong năm 2024, công ty đạt doanh thu $2.36B tăng so với doanh thu năm 2023, là $1.89B. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Neurocrine Biosciences, Inc. từ 2000 đến 2026
Doanh thu vào cuối mỗi năm
| Năm | Doanh thu | Thay đổi |
|---|---|---|
| 2026 (TTM) | $3.37B | 17.95% |
| 2025 | $2.86B | 21.45% |
| 2024 | $2.36B | 24.81% |
| 2023 | $1.89B | 26.76% |
| 2022 | $1.49B | 31.34% |
| 2021 | $1.13B | 8.38% |
| 2020 | $1.05B | 32.71% |
| 2019 | $788.10M | 74.67% |
| 2018 | $451.20M | 179.16% |
| 2017 | $161.63M | 977.51% |
| 2016 | $15.00M | -24.12% |
| 2015 | $19.77M | 0.00% |
| 2014 | 0.00 | -100.00% |
| 2013 | $2.92M | -94.51% |
| 2012 | $53.14M | -31.36% |
| 2011 | $77.41M | 131.08% |
| 2010 | $33.50M | 1,034.47% |
| 2009 | $2.95M | -25.71% |
| 2008 | $3.98M | 224.75% |
| 2007 | $1.22M | -96.88% |
| 2006 | $39.23M | -68.33% |
| 2005 | $123.89M | 45.45% |
| 2004 | $85.18M | -38.76% |
| 2003 | $139.08M | 670.73% |
| 2002 | $18.05M | -56.25% |
| 2001 | $41.24M | 182.71% |
| 2000 | $14.59M | 0.00% |
Doanh thu của các công ty hoặc đối thủ tương tự
| Công ty | Doanh thu | Chênh lệch doanh thu | Quốc gia |
|---|---|---|---|
| $12.62B | 274.18% |
US
|
|
| $2.23B | -33.96% |
US
|
|
| $15.74B | 366.65% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 78.47% |
NL
|
